PTK2 and hepatocellular carcinoma: To determine whether PRL-3 promotes FAK activation through TGF-β-Src signalling in HCC, we assessed the effects of a TGF-β receptor inhibitor, SB431542, and human recombinant TGF-β on FAK and Src activation.